News

Get the latest news
about MAbSilico's work and publications

Give us a call if you need more information or follow us on LinkedIn and Twitter.

All
Science
Business
Other
Business
Science

MAbSilico at AET form June 6 to 8.

May 30, 2023
May 30, 2023
Read More
Business
Science

MAbSilico at the BIO conference in Boston, June 5-8!

May 26, 2023
May 26, 2023
Read More
Business
Science

MAbSilico at PEGS!

May 8, 2023
May 30, 2023
Read More
Business
Science

Deciphering cross-reactivity. Read our new published paper !

August 26, 2022
May 25, 2023
Read More
Business
Science

TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity

June 27, 2022
May 23, 2023
Read More
Business
Science

MAbSilico invited by Perkin Elmer to give a talk in Paris

June 10, 2022
May 25, 2023
Read More
Business
Science

MAbSilico in Twist Bioscience webinar series

October 13, 2021
May 26, 2023
Read More
Business
Science

Accurate determination of epitope and epitope bins for antibodies with unknown 3D structures

July 23, 2021
May 25, 2023
Read More
Business
Science

Exploring epitope and functional diversity of anti-SARS-CoV2 antibodies using AI-based methods.

June 1, 2021
May 16, 2023
Read More
Business
Science

Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution

April 2, 2021
May 24, 2023
Read More
Business
Science

OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics

January 20, 2021
May 12, 2023
Read More
Business
Science

4C3 Human Monoclonal Antibody

September 29, 2020
May 23, 2023
Read More
Business
Science

MAbSilico deploys its AI tools for a fast response in context of pandemic threat

June 23, 2020
May 12, 2023
Read More
Business
Science

MAbSilico was given a little makeover

June 1, 2020
May 26, 2023
Read More
Business
Science

Biasing HER4 Tyrosine Kinase Signaling with Antibodies: Induction of Cell Death by antibody-dependent 4ICD Trafficking

May 16, 2020
May 23, 2023
Read More
Business
Science

MAbSilico presents its tools at the BIO Korea in partnership with Y-Biologics

May 5, 2020
May 25, 2023
Read More
Business
Science

MAbSilico awarded for a 1 M€ grant in the Bpifrance i-Nov competition

December 17, 2019
May 23, 2023
Read More
Business
Science

MAbSilico presenting at ComeUP 2019 in South Korea

November 1, 2019
May 16, 2023
Read More
Business
Science

MAbSilico at the Festival of Biologics, Basel, Oct 15-17

October 15, 2019
May 25, 2023
Read More
Business
Science

Methods to Determine Interaction Interfaces Between β-Arrestins and Their Protein Partners

May 3, 2019
May 23, 2023
Read More
Business
Science

A recycling anti-transferrin receptor-1 monoclonal antibody

May 2, 2019
May 25, 2023
Read More
Business
Science

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

May 2, 2019
May 25, 2023
Read More
Business
Science

MAbSilico is happy to announce the release of the scientific paper "MAbTope" in the Journal of Immunology.

September 10, 2018
May 25, 2023
Read More
Business
Science

G protein–dependent signaling triggers a β-arrestin–scaffolded p70S6K/ rpS6 module that controls 5′TOP mRNA translation

June 3, 2018
May 25, 2023
Read More
Business
Science

MAbSilico is incorporated!

September 25, 2017
May 26, 2023
Read More
Business
Science

5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies

August 8, 2017
May 12, 2023
Read More
Business
Science

Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges

November 25, 2016
May 25, 2023
Read More
Business
Science

Eculizumab epitope on complement C5: Progress towards a better understanding of the mechanism of action

June 9, 2016
May 23, 2023
Read More
Business
Science

MAbSilico at AET form June 6 to 8.

May 30, 2023
May 30, 2023
Read More
Business
Science

Deciphering cross-reactivity. Read our new published paper !

August 26, 2022
May 25, 2023
Read More
Business
Science

TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity

June 27, 2022
May 23, 2023
Read More
Business
Science

MAbSilico invited by Perkin Elmer to give a talk in Paris

June 10, 2022
May 25, 2023
Read More
Business
Science

MAbSilico in Twist Bioscience webinar series

October 13, 2021
May 26, 2023
Read More
Business
Science

Accurate determination of epitope and epitope bins for antibodies with unknown 3D structures

July 23, 2021
May 25, 2023
Read More
Business
Science

Exploring epitope and functional diversity of anti-SARS-CoV2 antibodies using AI-based methods.

June 1, 2021
May 16, 2023
Read More
Business
Science

Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution

April 2, 2021
May 24, 2023
Read More
Business
Science

4C3 Human Monoclonal Antibody

September 29, 2020
May 23, 2023
Read More
Business
Science

MAbSilico deploys its AI tools for a fast response in context of pandemic threat

June 23, 2020
May 12, 2023
Read More
Business
Science

Biasing HER4 Tyrosine Kinase Signaling with Antibodies: Induction of Cell Death by antibody-dependent 4ICD Trafficking

May 16, 2020
May 23, 2023
Read More
Business
Science

Methods to Determine Interaction Interfaces Between β-Arrestins and Their Protein Partners

May 3, 2019
May 23, 2023
Read More
Business
Science

A recycling anti-transferrin receptor-1 monoclonal antibody

May 2, 2019
May 25, 2023
Read More
Business
Science

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

May 2, 2019
May 25, 2023
Read More
Business
Science

MAbSilico is happy to announce the release of the scientific paper "MAbTope" in the Journal of Immunology.

September 10, 2018
May 25, 2023
Read More
Business
Science

G protein–dependent signaling triggers a β-arrestin–scaffolded p70S6K/ rpS6 module that controls 5′TOP mRNA translation

June 3, 2018
May 25, 2023
Read More
Business
Science

5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies

August 8, 2017
May 12, 2023
Read More
Business
Science

Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges

November 25, 2016
May 25, 2023
Read More
Business
Science

Eculizumab epitope on complement C5: Progress towards a better understanding of the mechanism of action

June 9, 2016
May 23, 2023
Read More
Business
Science

MAbSilico at the BIO conference in Boston, June 5-8!

May 26, 2023
May 26, 2023
Read More
Business
Science

MAbSilico at PEGS!

May 8, 2023
May 30, 2023
Read More
Business
Science

OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics

January 20, 2021
May 12, 2023
Read More
Business
Science

MAbSilico presents its tools at the BIO Korea in partnership with Y-Biologics

May 5, 2020
May 25, 2023
Read More
Business
Science

MAbSilico awarded for a 1 M€ grant in the Bpifrance i-Nov competition

December 17, 2019
May 23, 2023
Read More
Business
Science

MAbSilico presenting at ComeUP 2019 in South Korea

November 1, 2019
May 16, 2023
Read More
Business
Science

MAbSilico was given a little makeover

June 1, 2020
May 26, 2023
Read More
Business
Science

MAbSilico at the Festival of Biologics, Basel, Oct 15-17

October 15, 2019
May 25, 2023
Read More
Business
Science

MAbSilico is incorporated!

September 25, 2017
May 26, 2023
Read More
HomeTeamPartneringProcess
About usNewsUse casesContact
Terms and conditionsPrivacy policy
Contact us
MAbSilico. All Rights Reserved, 2023.
Designed with
by Storm Studio © 2023